The Chinese biopharmaceutical contract manufacturing market is estimated to be worth USD 2.6 billion in 2030
The growing biopharmaindustry in China has resulted in the creation of lucrative businessopportunities for contract service providers; region-specific advantages havealso attracted several foreign sponsors entities over the last few years
Roots Analysis is pleased toannounce the publication of its recent study, titled, “ChinaBiopharmaceutical Contract Manufacturing Market, 2020-2030.”
The report features an extensive study of thecurrent market landscape and future opportunities associated with the contractmanufacturing of biopharmaceuticals in China. The study also features adetailed analysis of key drivers and trends related to this evolving domain. Inaddition to other elements, the study includes:
§ A detailed assessmentof the current market landscape of companies offering contract manufacturing servicesfor biopharmaceuticals in China.
§ An analysis of thepartnerships that have been established in this domain, in the recent past.
§ An analysis of theexpansion initiatives undertaken by contract manufacturers in China, in orderto augment their capabilities, in the recent past.
§ A detailed analysisof more than 1500 clinical trials related to biopharmaceuticals that have been/ are being / are likely to be conducted in China.
§ An estimate of theoverall, installed capacity for manufacturing biopharmaceuticals, based on datareported by industry stakeholders in the public domain.
§ An analysis of the initiativesof big biopharma players engaged in this domain.
§ A qualitativeanalysis, highlighting the various factors that need to be taken intoconsideration by drug / therapy developers while deciding whether tomanufacture their respective products in-house or engage the services of a CMO.
§ Detailed profiles of keyplayers that have a diverse range of capabilities for the development, manufacturing,and packaging of biopharmaceutical products.
§ A case studycomparing the key characteristics of large molecule and small molecule drugs.
§ A discussion onindustry affiliated trends, key drivers, and challenges, under a SWOTframework, which are likely to impact the evolution of this field.
§ A detailed market forecast, featuring analysis of thecurrent and projected future opportunity across key market segments (listedbelow)
- Type of Product
§ API
§ FDF
- Type of Expression System Used
§ Mammalian
§ Microbial
§ Others
- Scale of Operation
§ Preclinical /Clinical
§ Commercial
- Size of Manufacturer
§ Small
§ Mid-sized
§ Large / Very Large
- Type of Biologic
§ Antibody
§ Vaccine
§ Others
Keycompanies covered in the report
§ ChemPartner Biologics
§ JHL Biotech
§ JOINN Biologics
§ MabPlex
§ Mycenax Biotech
§ WuXi AppTec
Formore information please click on the following link:
Other RecentOfferings
1. China PharmaceuticalContract Manufacturing Services Market, 2020-2030
About Roots Analysis
Roots Analysis is one of the fastest growingmarket research companies, sharing fresh and independent perspectives in thebio-pharmaceutical industry. The in-depth research, analysis and insights aredriven by an experienced leadership team which has gained many years ofsignificant experience in this sector. If you’d like help with your growingbusiness needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
